Neonatologists from the University of Padova in Italy conducted a systematic review of 26 case reports and case series regarding clinical outcomes of neonates with COVID-19 published between December 2019 and May 2020 (Figure 1). In 44 newborns with confirmed SARS-CoV-2 infections, they found neonates were diagnosed at a median of five days from birth, with 25% presenting asymptomatically and the rest presenting with mild symptoms. Symptoms resolved in all after 10 days of hospitalization (Table 3). Based on these early findings, authors suggest SARS-COV-2 infection in neonates is generally mild but emphasize the need for larger rigorous studies in this area.

A literature review conducted by researchers affiliated with the Tehran University of Medical Sciences and Shahid Beheshti University of Medical Sciences examined 176 studies published between June - October 23, 2020 in the PubMed, Google Scholar, and Medline databases investigating the use for antiretroviral therapy in pre- or post-exposure prophylaxis against COVID-19 infection (Figure 1). The authors found no definitive current evidence to support the role of antiretroviral therapies, however there are multiple ongoing studies looking at the role of protease inhibitors, Tenofovir, and emtricitabine (Table 1). The results of this liturature review and current studies could be invaluable for patients with HIV/AIDS or a contraindication to receiving the COVID-19 vaccines.

​

​

​